JonesTrading Maintains Buy on CymaBay Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Prakhar Agrawal maintains a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $13 to $15.
August 15, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JonesTrading analyst Prakhar Agrawal maintains a 'Buy' rating on CymaBay Therapeutics and raises the price target from $13 to $15.
The raised price target by JonesTrading indicates a positive outlook for CymaBay Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100